TGFB1 and hepatocellular carcinoma: In HCC patients that were ineligible for Sorafenib, treatment with Galunisertib has been reported to increase the overall survival (7.91 months in patients with a reduction of TGF-β less than 20% vs. 21.8 months in patients with a reduction of TGF-β more than 20%) [226].